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FRAUD AND ABUSE PANEL 
 
 
FEATURING: ELLEN BOWDEN MCINTYRE, ASSISTANT 
UNITED STATES ATTORNEY MIDDLE DISTRICT OF 
TENNESSEE,* 
 
PATSY POWERS, WALLER, LANSDEN, DORTCH & DAVIS, 
 
AND 
 
BRIAN ROARK, BASS, BERRY & SIMS 
 
 
Moderated by Daniel Patten, Waller Lansden, Dortch & Davis 
 
January 27, 2017 
 
 
Zach Gureasko:  All right. If you can all take your seats, please, 
we’re going to go ahead and get started again. I am going to 
introduce our moderator, Daniel Patten. Before I do so, Aubrey 
briefly alluded to our online Health Law Journal. I just wanted to 
make you guys aware of a particular date. We accept practitioner’s 
submissions and we accept them on a rolling basis, but we basically 
have a deadline in the spring and a deadline in the fall. We don’t 
have the fall set up yet, but the deadline in the spring is March 3rd. 
Some time within the coming days, the person in charge of our 
website will open a portal where you can drop your submissions, 
and this can be anything from a full article to a short essay. Ideally 
something longer than maybe you would see on like a blog post, 
but just, you know, anything you have that you want to submit to 
us, we are happy to take. Again, that deadline is March 3rd and that 
will be through a portal on our website. Then we’ll have selected 
those submissions that we will publish by March 31st. Again, we’ll 
be accepting them at any time, but we just have two firm deadlines 
                                                
* The views of Ms. McIntyre expressed here are her own personal views and do not 
necessarily reflect the views of the U.S. Attorney’s Office or the Department of Justice. 
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just to enable us to kind of review the things that have been 
submitted, discuss, and decide which ones are going to be 
published. The second part that I wanted to talk about is the blog 
that we have on that website, again, healthlaw.belmont.edu. The 
blog is student led and we’re going to keep it updated regularly with 
the happenings in the health care community. As we all know, these 
change every hour in the health care community so we’re going to 
keep that updated very frequently with submissions from our 
students. So I just wanted to get that deadline out there as well as 
generate some interest in the blog, and have you start looking at 
that for some guidance in some of these issues that we’ve been 
talking about and will continue to talk about.  
 
Now, we’re going to have a panel discussion on some concerns that 
we have about value based reimbursement structures, and our 
moderator is going to be Daniel Patten. Daniel graduated with his 
Bachelors from Wake Forest University, and then he received his 
J.D. here at Belmont University College of Law with high honors. 
While he was here, he received the Health Law Certificate and the 
ABA BNA award for excellence in the study of health law. He was 
also the executive editor of the Belmont Law Review and he is now 
in his third year working for Waller in the health group focusing on 
transactional and operational issues. He’s going to go ahead and 
introduce the rest of the panelists, but if you’ll join me in welcoming 
Daniel Patten.  
 
Daniel Patten: Thanks, Zach. I’m excited to be here, back at 
Belmont. Just before we begin I want to say that the quality of the 
health law program Belmont has established is a testament to Debbie 
Farringer’s hard work. All of these questions originated from 
student questions and ideas, which made my job a lot easier. I want 
to thank the students for putting that together. The panel today 
consists of two private practice attorneys and one government 
attorney. We have litigators and regulatory attorneys, so a good mix 
of attorneys across the spectrum.  
 
Starting on the far end is Brian Roark, who is the head of the Bass, 
Berry & Sims healthcare fraud task force. He’s also an adjunct 
professor at Vanderbilt University, teaching Fraud and Abuse and is 
the chair of the health law section of the TBA.  
 
To his left is Ellen Bowden McIntyre, who is an assistant U.S. 
Attorney in Nashville.  She has been there since 2003 and handles 
various cases primarily on the False Claims Act1 and other health 
                                                
1 31 U.S.C. §§ 3729-3733 (2009). 
18 BELMONT PRACS. GUIDE TO HEALTH L. & POL’Y VOL. I 
 
care fraud, on both the civil and criminal side. She attended Penn 
and received her J.D. from Columbia Law. Before she was an 
AUSA, she served as a senior trial attorney at the Justice 
Department’s Civil Rights Division, and worked as a staff attorney 
at the Southern Poverty Law Center. 
 
Finally, to Ellen’s left, is Patsy Powers. Patsy is a partner at Waller 
and her office is two doors down from me, most importantly, right? 
She earned her B.S. at Vanderbilt and her J.D. at Tennessee College 
of Law.  Patsy serves on the board of the Sloam Family Health 
Center.  
 
So, to kick things off for the Fraud and Abuse panel, I would like to 
start with the private practice attorneys.  What are some current 
challenges for clients, and where do you see the biggest challenges 
for your clients today in connection with the appliance of fraud and 
abuse?  Additionally, what are some potential effects or potential 
concerns moving forward with the repeal of ACA2? 
 
Patsy Powers: Anybody who’s in the healthcare industry is familiar 
with and used to change. They’re used to changing laws, changing 
regulations, and to a certain extent, changing enforcement. But, I 
think, what we’re seeing now, is a wave of change that is far greater 
than what most people have ever expected. It’s not only related to 
the Affordable Care Act but also the changing enforcement climate. 
My favorite example is employment of physicians. For years, 
employing physicians was the safest way for a hospital to engage 
with their practitioners because there is an applicable safe harbor,3 
an exemption under the anti-kickback statute, and a Stark Law 
exception.4 It was very easy for hospitals to employ physicians if the 
parties were not in a corporate practice state. And so, assuming that 
you are not in a corporate practice state, it was a nice way to go. 
Recently however, although the law hasn’t changed, and the 
regulations haven’t changed. The qui tam relators became very 
active, with the result being that the enforcement climate has 
changed. The result is that the definition of “commercial 
reasonableness,” an element in the Stark Law employment 
exception, 5   is closely scrutinized by whistleblowers. The most 
obvious scenario is a physician whose professional collections are 
less than his salary. Absent countervailing circumstances like high 
indigent population, poor payer mix, or difficulty retaining a 
specialty, the relationship may be prosecuted as an arrangement that 
                                                
2 42 U.S.C. §300gg (2010). 
342 C.F.R. § 411.357 (2017).  
4 Id. 
5 Id. 
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is not commercially reasonable. The enforcement climate has 
upended our view of what’s safe, what’s comfortable, and what are 
safe financial relationships for our clients to have with physicians.   
 
Brian Roark: Yeah, I would agree with Patsy. The biggest 
challenge is the overwhelming complexity of the laws and 
regulations that are out there. But as Patsy said, that’s already baked 
into the DNA of a lot of health care companies. I would say that one 
of the biggest challenges today, in particular sometimes for smaller 
health care companies, is dealing with so much regulation or so 
many different outside entities that are looking into what they are 
doing that forces them into a position of having to be a lot more 
reactive than proactive. One of my clients used a term this week that 
I like a lot, which is they sometimes feel like there is “regulatory 
harassment.” That many times, obviously excluding Ellen, 
sometimes in the government there can be a tendency to paint with 
a broad brush. A lot of companies out there feel like they are really 
trying to do things the right way, but that doesn’t mean that they are 
always perfect, and many times they may violate a particular 
regulation. Sometimes the government doesn’t see that and 
appreciate that the cost of dealing with an investigation or defending 
a matter—just the cost of that—even if they’re ultimately able to 
show that they didn’t do anything inappropriate, can be 
overwhelming. And I would say, one of the big things that we’re 
watching in my sector on the litigation side, is not necessarily just 
changes in the ACA and what may come from that, but what’s going 
to happen with government enforcement under the Trump 
administration. Health care fraud enforcement is not a partisan issue. 
Just because the Republicans are now in charge doesn’t mean that 
fraud enforcement is going to decline. One of the biggest proponents 
of the False Claims Act6 is a Republican senator from Iowa, Senator 
Grassley. That being said, we are waiting to see how the Trump 
administration may change focus. Is there going to be more focus on 
areas like immigration, and is that going to mean less enforcement 
on things like health care fraud? And then I just want to mention, 
locally, there is a great article that came out yesterday in the 
Nashville Scene about what may happen with changes with U.S. 
attorneys and with judges in Nashville.7 The article features a lot of 
interesting quotes from Dean Gonzales here at Belmont, reflecting 
on his experiences as Attorney General. Plus, we’re waiting to see 
if there is a new U.S. Attorney in Nashville and how will that change 
the focus. And then, news from just yesterday, or two days ago, the 
                                                
6 31 U.S.C. §§3729-3733 (2009).  
7 Stephen Elliot, Order in the Court: Nashville's Federal Judiciary Enters Trump's 
America, NASHVILLE SCENE (2017), available at 
http://www.nashvillescene.com/news/features/article/20850167/order-in-the-court.  
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Middle District of Tennessee has four judges, lifetime appointments. 
The Chief Judge in Nashville, Kevin Sharp, announced that he is 
resigning and stepping down from the bench and is going into 
private practice. Interestingly, he is going to open the Nashville 
office of a qui tam whistle blower law firm, Sanford Heisler. So read 
into that what you will. But you know, it’s extremely interesting in 
Nashville that you have someone leaving lifetime appointment 
who’s going to go over and do plaintiff’s side health care fraud 
cases.  
  
Daniel Patten: Talking about the False Claims Act, which I think 
we all agree is a well-used arrow in the quiver of the government, 
last year the Supreme Court decided a case of Universal Healthcare 
in U.S. ex rel. Escobar v. Universal Health Services, Inc.,8 which 
analyzed the theory on implied false certification that many courts 
have been using for purposes of determining liability under the False 
Claims Act. Ellen, if you could tell the group who might be 
unfamiliar with this issue, a little about the background of the case, 
the circuit split, and discuss this new definition of materiality. How, 
under Escobar, pleadings may have changed or just generally how 
it may have changed the litigation of these cases.  
 
Ellen McIntyre: Sure, and just a tad bit of background on the case 
in case folks here haven’t read it. Basically, it came out of a 
Massachusetts District Court False Claims Act case, in which a 
Medicaid recipient had gotten services from Universal Health 
Services, which gave counseling services, prescribed medicine, and 
that sort of thing. It turned out that 23 of the providers there actually 
weren’t properly licensed to be doing what they were doing -- like 
they had nurses who were not supervised who were prescribing 
medications. All this was in violation of Medicaid requirements in 
the State of Massachusetts. But these requirements were not 
expressly designated as a condition of payment. And so, therefore, 
a whistleblower filed a False Claims Act lawsuit, and the District 
Court granted the motion to dismiss because this violation—
although clearly not legal—was not expressly designated as a 
condition of payment, which has been an issue brewing in the circuit 
courts. The case winds up at the Supreme Court, and the Supreme 
Court had two big rulings. Number one, an implied certification, in 
other words, submitting a claim in which you’re not complying but 
you’re not saying, “I am complying,” can be an actionable False 
Claims Act violation. So the Court endorsed that theory, which was 
mostly endorsed out there but there were still some arguments about 
it. So that can be a basis for liability, and it can constitute a 
                                                
8 Universal Health Servs., Inc. v. United States ex rel. Escobar, 136 S. Ct. 1989 (2016). 
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misleading half-truth, the term that the Supreme Court used.9 The 
Court also said that you don’t have to have an express condition of 
payment. It is relevant and you can look at that, but the absence of 
an express designation of a condition of payment is not dispositive. 
You can look at other things. The key question is materiality, and 
that’s the other big ruling. Escobar gives a big explanation of what 
the Supreme Court expects the materiality standard to be, and the 
Court tweaked that language a little bit. So what the Court said about 
materiality is that you can look at it from two perspectives: one is 
the perspective of a reasonable person and would they think that 
something is a material condition of payment. Or, you can also look 
at it from the perspective of the likely or actual behavior of the 
recipient, even if a reasonable person doesn’t value it.10 So you sort 
of have two doors that you can fit through whether you’re a 
regulator, or the U.S. government, or a state government. And so, 
that’s obviously a significant ruling, as a June 2016 Supreme Court 
case.  
 
The other part of the question was how pleadings change. From the 
government’s perspective, I don’t think it really changes so much 
about what we thought was required, but clearly the language is a 
little bit different now. Like for one, I don’t think we were focusing 
on reasonable person or, putting conduct in specific, linguistic 
boxes. So I think it’s definitely true that if the government files a 
complaint in intervention in a qui tam or if we file our own original 
case without a qui tam, the government is going to try to track that 
Escobar language and fit within that language. I think we were 
already basically doing that. But having said that, the government is 
going to be more careful, and probably good lawyers are going to be 
more careful in the way they plead things. Obviously these 
arguments are going to come up from the defense, and I would let 
Brian segue into that, but this is the new standard. It is not really that 
different from the old standard.  
 
Brian Roark: Yeah, the government has been taking the position 
that Escobar did not really change anything. The defendants, on the 
other hand, say it’s a radically different and much higher standard 
in terms of what a plaintiff has to show to be able to establish 
liability under the False Claims Act. The example that I like to use 
to talk about Escobar is alcohol-based hand rub dispensers because 
nobody ever expects to talk about that. There are, please look it up 
afterwards, there are significant federal regulations specifying for 
hospitals, for ambulatory surgery centers, not only that they have to 
have alcohol-based hand rub dispensers but how they’re supposed 
                                                
9 Id. at 2001.  
10 Id. at 2003.  
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to be installed, and where they can be and where they can’t be. That 
is a federal regulation. If you think about that being on one end of 
the continuum, that if a hospital violates that regulation in some 
way, really nobody thinks you can bring an FCA case on that basis. 
On the other end of the spectrum, let’s say you have the Anti-
kickback statute or the Stark law. If you violate the Anti-kickback 
statute, everyone understands you can be sued under the FCA for 
that.11 So if those are the two ends of the spectrum, you have all this 
area in between of the thousands of regulations that are out there. If 
you violate this particular one, does that subject you to FCA 
liability? Does that mean you potentially, by being in violation of 
that, in billing Medicare that you might be required to make a 
repayment? And Escobar attempted to weigh in on that question, 
but the parameters it has put around that question in some ways has 
made it harder for providers these days. Previously, the rule was 
more around if something is labeled as a condition of payment, then 
you could be liable under the FCA. But if it’s labeled a condition of 
participation, if it just goes to a survey issue, you couldn’t. The 
Supreme Court said we’re not going to apply the test that just looks 
at that label because that would make it too easy for the government 
to put that label on every single regulation. Instead, we’re going to 
get into “do you really think that this is essential to the services that 
are being provided?” But I mean, Patsy, in your practice has this 
made it harder? 
 
Brian Roark: And I would agree with Ellen, that Escobar is not 
changing very much the kinds of cases that the government is going 
to be bringing under the FCA, but you still have to deal with a lot of 
these crazy whistleblowers and relators out there, who might really 
might bring an FCA lawsuit about hand dispensers or something 
else. The government may decline that lawsuit but more and more 
often defendants are still having to go and litigate with relators over 
some of these issues.  
 
Ellen McIntyre: It is true that getting rid of the condition of 
payment—sort of bright line test—makes it easier for the 
government to bring certain cases where there wasn’t an express 
designation, because that limitation has now gone away. Now there 
is still a test obviously. But yes, I agree, it is a subjective test.  
 
Daniel Patten: So moving from the relator or the government 
coming after providers aspect of the False Claims Act, I would like 
to focus on the self-policing aspects of self-disclosure. CMS12 and 
                                                
11 31 U.S.C. § 3730 (2010). 
12 Self-Referral Disclosure Protocol, Ctrs. for Medicaid & Medicare Servs. (2017), 
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OIG,13 the protocols they released have been out for some time. I 
know on the CMS side, the increase in volume and the response has 
been quite delayed. Patsy, could you speak on where you see the 
system right now? Has the government been effective in 
communicating or clarifying that process?  Do you think that 
process is developing in a positive way? 
 
Patsy Powers: The process is a mystery. The positive aspect of the 
CMS Self-Referral Disclosure Protocol is that the final settlement 
amount is much less than the penalties due and owing in an initial 
disclosure. The CMS disclosure protocol for Stark violations 
generally is that you disclose to CMS each way that you violated 
Stark and the amount of money that you owe back to the government 
for each of those violations. Then you get an email from CMS 
confirming they received the disclosure. It’s often years before you 
hear anything else. Sometimes it is difficult to even identify the 
person reviewing the disclosure. You have to really work with CMS 
and find the right person, and even then, CMS won’t tell you 
anything. Similarly, on its website, CMS identifies past settlements 
and the amounts of the settlements, but not the amount that was 
originally submitted with the disclosure.14 But by word of mouth 
and experience, we’ve learned that the settlements generally range 
between six to ten percent of the disclosed amount received by the 
provider from claims tainted by a Stark violation. So if it’s a $70 
million disclosure, then the settlement may be $7 million. So that’s 
helpful because that takes some of the difficulty away from the 
process when you can advise a client that even though they disclosed 
$10 million in tainted claims, they will probably have to pay less 
than a million dollars. But there is no certainty to that six to ten 
percent range. That’s just been the typical experience so far, which 
is better than it could be, CMS could be trying to collect 100%. 
There is also a lot of conversation in Washington about changing 
Stark and maybe keeping the prohibition related to physician 
investment in entities that provide designated health service. CMS 
certainly has reduced the burden of Stark in certain respects with the 
changes that came about last year. For example, CMS clarified that 
the written agreement requirement for certain compensation 
arrangements can be satisfied by a collection of either emails or 
letters or documents or board minutes that can be pieced together to 
establish a written arrangement.15 CMS also lessened the rules for 
                                                
 https://www.cms.gov/Medicare/Fraud-and-
Abuse/PhysicianSelfReferral/Self_Referral_Disclosure_Protocol.html [hereinafter “Stark 
Self-Disclosure Protocol”].  
13 Provider Self-Disclosure Protocol, Office of Inspector Gen., U.S. Dep’t of Health and 
Hum. Servs., https://oig.hhs.gov/compliance/self-disclosure-info/protocol.asp. 
14 See Stark Self-Disclosure Protocol, supra note 12.  
15 42 C.F.R. 411.357 (2017); 80 Fed. Reg. 70886, 71315-17 (Nov. 16, 2015). 
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holdover leases so that the time period for a holdover, rather than 
just being six months, can continue for a longer period of time so 
long as the rent paid during the holdover remains fair market value.16 
So, while CMS has lessened the burden a little on providers, the 
disclosure process is really a black box. And, at the end of the day 
if CMS comes back and says, “You owe us a million dollars,” there 
isn’t a discussion about it. It’s just, “here’s where you are,” which is 
a little disturbing because providers don’t really have any 
opportunity to discuss it, negotiate or anything.  
 
Brian Roark: Yeah. I would agree. CMS has really pushed and 
encouraged providers to use the self-disclosure protocol. At the 
same time, CMS discloses very little information about matters that 
have been successfully resolved. So if you’re a provider, there’s 
very—absent being able to talk to another company about what 
result they had, absent being able to talk to an attorney who might 
be able to share information about a past experience--there’s very 
little insight. At the end of the day, if we have a client that finds a 
very obvious issue, you’ve been paying a physician and there’s no 
written agreement and there’s nothing to argue that there’s a written 
arrangement, they will use the Stark Self-Disclosure Protocol. But 
for other issues, we really look creatively for ways to not.  
 
Daniel Patten: So, we talked about False Claims liability often 
being connected to liability under the Anti-Kickback Statute17 and 
the Stark Law.18 Anti-kickback being the foundation for a lot of 
these claims, which came about in contemplation of a fee-for-
service system. Today, however, reimbursement is switching to 
more of a value-based system. CMS has announced that its goal is 
to have 50 percent of all reimbursements for medical services under 
value-based reimbursement methodology.19 How will we see this 
shift? How will that impact the fraud and abuse laws? Are we going 
to see more waivers? Are they going to lose their teeth? Could this 
have downstream impacts on FCA, litigation and potential lawsuits 
in the future? 
 
Patsy Powers: That remains to be seen. The whole premise of the 
Anti-Kickback Statute and Stark Law, in respect to payments to 
physicians, is that the payments are fair market value. Under value-
                                                
  
16 42 C.F.R. 411.357(a)(7) (2017); 80 Fed. Reg. 70886, 71319-20 (Nov. 16, 2015).  
17 42 U.S.C. §1320a-7b (2015). 
18 42 U.S.C. § 411.1395nn (2010). 
19 What Is Value-Based Care, What It Means for Providers?, REVCYCLEINTELLIGENCE 
(2016), http://revcycleintelligence.com/features/what-is-value-based-care-what-it-means-
for-providers. 
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based payment models, payments to physicians should still be fair 
market value. Of course, with some value-based payment models 
there may be a bucket of shared savings to be divided among 
physicians, a hospital, a home health agency, etc. If for example, 
you go to a hospital for a hip replacement and each of the various 
providers sufficiently participate in the patient’s care, then each of 
the providers should enjoy the benefit of the shared savings money. 
If, however, any of the money paid to a physician is above fair 
market value, then is that a problem? It shouldn’t be, which is 
partially why the ACOs have waivers to the anti-kickback statute 
and Stark Law that are broad, you just have a waiver. For other 
arrangements, there need to be similar waivers to protect reasonable 
payments to physicians. The prior panel talked about how the 
commercial payers, Medicaid, and Medicare all have to have, to 
some extent, a common payment methodology so that providers do 
not have to abide by different programs and arrangements. And so, 
if say a commercial payer and Medicare each have similar 
requirements for bundled payments, then that works very well in 
terms of care delivery and the documentation required. But, the 
money from each payer might not be the same. Dr. Farringer might 
receive $10,000 in bonuses for patients treated efficiently while 
participating in a bundle for Blue Cross and a substantially similar 
bundle for Medicare. The question then becomes whether that 
$10,000 payment is for the right mix of patients or not. In other 
words, is the right amount being attributed to Medicare versus Blue 
Cross? Should providers really have to track that? Should they have 
to track whether or not that’s a fair market value allocation of the 
bonus for the commercial insurance, Medicare and Medicaid? That 
would be very difficult and that sort of compliance effort arguably 
shouldn’t be necessary. If you’re doing the job well, you’re 
providing quality service and you’re engaging in these alternative 
payment models, should you really have to worry about fair market 
values? And so more waivers, I think, are appropriate. But in the 
meantime, we’re sort of living in both worlds. And that is what 
Michael was saying—it’s a challenge, operating a hospital right now 
in all of these different worlds is a huge challenge. So yes, more 
waivers are necessary.  
 
Brian Roark: As Daniel phrased the question; the Anti-Kickback 
Statute and Stark Law rose out of a fee-for-service reimbursement 
system, with the thought being that those laws were the proper ways 
to govern excesses in that type system. As we move away from fee-
for-service reimbursement, we move towards encouraging more 
integration between the hospital and rehab, or the hospital and a 
home health company. Arrangements that are viewed suspect under 
Stark Law or Anti-Kickback are exactly what the government or 
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payers are trying to encourage these days and the law no longer fits 
that. I wish that I were smart enough to say, “Here are the ways to 
change the law.” It’s either waiver, or it’s either when we’re dealing 
with fee-for-service kind of payment structures, potentially doing 
away with it all together.  
 
Daniel Patten: For the litigators here, do you see any issues that are 
starting to arise in district courts and courts of appeals in connection 
with fraud and abuse laws that have an impact on current approaches 
to compliance? 
 
Ellen McIntyre: Well in general, of course, there’s just more qui 
tams. This means both that the government ends up intervening in 
more qui tams, but also that the government still declines a chunk of 
qui tams. One change is that a lot of those relators are going forward 
without the government, which didn’t used to happen. Now 
obviously this has spillover effects in terms of what providers do, 
and it probably is sort of a policing tool, even if it hasn’t hit a 
particular provider with a suit being filed against them.  
 
There is also of course a huge increase in recoveries annually by the 
federal government. I think that the government got an additional 
billion dollars over last year. These are gigantic numbers. I think 
also that it’s not so much based on a change in the law, but just kind 
of a change in the climate, with all of these factors.  
 
There is also an expansion of things that the government is looking 
at, and not just in terms of what comes in the door and what a 
whistleblower might file. Such as, in our district, in the Middle 
District of Tennessee, we are one of ten districts in the U.S. that 
launched its own Elder Justice Task Force in 2016.20 The Justice 
Department has also created an Elder Justice website, which is a new 
initiative. There are various ways in which most people might not 
think of Elder Justice, for instance, as something that could be the 
subject of a False Claims Act action. But elder issues are increasing 
around the country. Look at skilled nursing facilities, look at the 
quality of care concerns. Quality of care is probably increasingly 
going to be something that the government looks at when they’re 
thinking about False Claims Act concerns and how it impacts patient 
care. Are patients getting what they should be getting? As opposed 
to the Purell example. I don’t think we were ever focusing on Purell. 
I’ve never seen a case about Purell.  
 
                                                
20 Elder Justice Task Forces, The U.S. Dep’t of Justice, 
https://www.justice.gov/elderjustice/task-forces (last visited Dec. 28, 2017). 
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Brian Roark: Not yet.  
 
Ellen McIntyre: I’m not going to say too much about that. The 
government is concerned about serious violations that impact 
patients or the government fisc in significant ways. Sometimes 
people just think about only hospitals being affected, and I don’t 
mean that the hospitals don’t have to comply, but it’s sort of a big 
picture. The big picture is just services that Medicare and Medicaid 
fund, and whether there are substantial false claims in conjunction 
with those services across the board. That’s my general insight.  
 
Brian Roark: I would add a couple of trends that I have seen: One, 
the government’s increasing use of data, which is not a new trend 
for you all here, but more of just—I think in the past, for a lot of 
AUSAs like Ellen, if they wanted to analyze some data, that would 
require making a request and getting some specialists to come and 
help them. These days, what I have seen is that it is just much easier 
for AUSAs, while they’re on the phone with you, to be able to pull 
up on their computers and see for this particular doctor, is this doctor 
fiftieth percentile for whatever particular procedure, is this doctor 
ninetieth percentile, is this doctor off the charts. Also, where the 
government may start an investigation looking at issue A: Someone 
files a qui tam, a qui tam makes allegations about this doctor’s lease 
arrangement. The government looks into that and finds that there’s 
not really support of that. But, oh by the way, as long as they’re 
looking into that doctor’s lease arrangement, what they do notice is 
this doctor appears to be an outlier with respect to how many stents 
he or she is doing in the state of Tennessee versus other doctors. I’ve 
been amazed at how much of this data you can even pull up on the 
Wall Street Journal or the Open Payments website21 just to see for 
a particular physician, you know, if the number one doctor in the 
state—or number two doctor in the state for stents that $3 million in 
Medicare reimbursements last year. It sort of stands out if number 
two is $3 million and number one is at $9 million. It stands out, and 
the government, in my view, is paying closer attention to that. The 
other item that I would mention that is really significant right now 
is what’s going to happen in terms of statistical sampling. If the 
government is investigating conduct that went on at ten different 
facilities, if they say we think these ten facilities are providing too 
much therapy or therapy at too high a level, and we think that that 
touches on 40,000 claims over this time period, the government 
wants to move forward on a medical necessity issue. Can the 
government simply put on proof on what happened with respect to 
40 patients and say that that then extrapolates across the 40,000? Or 
                                                
21 Open Payments, Ctrs. for Medicaid & Medicare Servs., 
https://www.cms.gov/openpayments/ (last modified Dec. 01, 2017). 
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is the government obligated to go and prove fraud with respect to, 
brick by brick, each individual case? It’s the difference in, is the trial 
going to last one week? Is the trial going to last one year? The scary 
part about a trial lasting one-week is it makes it very easy for the 
government to be able to bring some really massive fraud cases and 
have a big swing in the balance just based on how the proof may 
come in on a handful of patients.  
 
Daniel Patten: Do you see an increase in relying on contractors, 
such as ZPIC’s? It is a good way to provide oversight at a low cost 
to the government.  
 
Brian Roark: I see it continuing. I think under a Republican 
administration, that you will see more outsourcing and the continued 
pushing of audit and compliance function to outside third parties and 
giving them some incentive to go and find the fraud. I think there’s 
some scary stuff going on in some jurisdictions right now. In the 
state of Florida right now, long term care and home health, just sort 
of some out of control payment suspensions that the ZPIC in Florida 
has been instituting right now. In a system where you’re dealing 
with a ZPIC, if they’re out of control, what do you do about that? 
You know, if the ZPIC doesn’t work for Ellen, and I’m not really 
sure that they work for CMS. They can put providers into difficult 
circumstances with few ways to make that stop.  
 
Ellen McIntyre: Although, I think that’s usually discussed with 
CMS. But yes, I think there are more payment suspensions. I think 
that’s correct.  
 
Patsy Powers: The data issue is a big one. The government has 
access to all kinds of data, and that’s only increasing as our delivery 
systems and payment models become more sophisticated and 
providers collect and report more and more data on quality, 
outcome, utilization and more. For example, data about how many 
times I tell my doctor I might take my medications each month, very 
personal health data is being collected. There are all kinds of data 
that a provider is required to report under new payment systems, and 
we don’t know yet all the different ways that a provider might 
accurately report or inaccurately report. But we do know that there 
are, and likely will be, ways for a provider to increase their 
reimbursement depending on the data reported under these new 
payment systems after 2019. So, the use of the data, the accurate 
reporting of the data, and the accurate review of the data is going to 
transform things significantly. It’s not clear yet how this 
transformation will play out. But it could be very, very significant, 
depending on how these third party contractors who are empowered 
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to review the data, slice and dice it in different ways. A provider 
might not even know who’s looking at their data.  
 
Daniel Patten: For the last few minutes, I want to open it up for 
questions.  
 
 
